TherapeuticsMD, Inc.
For the period ended Dec 31, 2024. Filed Mar 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 27, 2025
TXMD$1.74+3.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
Consolidated Statements of Cash Flows
(In thousands)
| Years ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities: | ||
| Net loss | $(2,181) | $(10,278) |
| Less: Income (loss) from discontinued operations, net of tax | 131 | (2,579) |
| Net loss from continuing operations | (2,312) | (7,699) |
| Adjustments to reconcile net loss to net cash used in continuing operating activities: | ||
| Depreciation and amortization | 509 | 922 |
| Impairment of long-lived assets (Note 4) | 1,268 | — |
| Share-based payment compensation costs | 264 | 1,271 |
| Other | (219) | (129) |
| Changes in operating assets and liabilities: | ||
| Prepaid and other current assets | 397 | 1,999 |
| Other assets | 1,930 | (1,126) |
| Accounts payable | 231 | (2,135) |
| Accrued expenses and other current liabilities | (1,006) | (15,713) |
| Other non-current liabilities | 108 | (471) |
| Total adjustments | 3,482 | (15,382) |
| Net cash provided by (used in) continuing operating activities | 1,170 | (23,081) |
| Cash flows from continuing financing activities: | ||
| Proceeds from sale of common stock, net of costs | — | 3,151 |
| Net cash provided by continuing financing activities | — | 3,151 |
| Discontinued operations: | ||
| Net cash used in operating activities | (438) | (25,060) |
| Net cash used in discontinued operations | (438) | (25,060) |
| Net increase (decrease) in cash | 732 | (44,990) |
| Cash and restricted cash - continuing operations, beginning of period | 4,327 | 49,317 |
| Total cash and restricted cash, end of period | $5,059 | $4,327 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.